The forthcoming ENTRACTE trial results (https://clinicaltrials.gov/ct2/show/NCT01331837), are highly anticipated and will directly compare the IL‐6 receptor blocker tocilizumab with the TNF‐α blocker etanercept in the prevention of CVD events in RA patients for the first time, but will not be able to test the inflammatory hypothesis directly. Here, TNF is linked to rheumatoid arthritis.